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Introduction

Background & Significance

•

Opioid use disorder (OUD) is an epidemic in
the U.S. that effects both the mother’s and
the infant’s health (Zedler et al., 2016)

Morbidity
Statistics
Among Infants

•

Infant’s exposed to addictive illicit or
prescribed substances suffer from
decreased health outcomes such as longer
hospital stays, low birth weight, preterm
birth, and neonatal abstinence syndrome
(NAS) (Okoroh et al., 2017).
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•

•

•

NAS is a group of symptoms experienced
by a newborn infant that was exposed to
addictive drugs in the womb (Corr &
Hollenbeak, 2017)
The aim is to identify infant health outcomes
when pregnant women are prescribed
medication-assisted treatment (MAT) for
OUD.
Among pregnant women with OUD in the
U.S., is MAT as compared to no therapy
associated with decreased negative infant
health outcomes?
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•

Infants with NAS had hospital stays that
were 3.5 times longer than infants without
NAS (Corr & Hollenbeak, 2017).

•

Approximately, one-third of infants with NAS
are cared for in smaller hospitals that may
not have the resources needed for their
care (Corr & Hollenbeak, 2017).

•

Prevalence of OUD has increased by more
than double from 1998 to 2011 among
pregnant women, which increases the
likelihood of adverse outcomes (Zedler et
al., 2016).

To decrease prenatal drug exposure,
leadership is needed among public health to
inform and provide resources to women of
childbearing age (Corr & Hollenbeak, 2017).

Databases: CINAHL, PubMED

•

Keywords: opioid use disorder, pregnancy,
neonatal abstinence syndrome

•

Search Limitations: 2016-2021, full text
only

•

Inclusions: One qualitative and three
quantitative articles were used from 815
results focusing on infant outcomes and
prevention of NAS. One meta-analysis was
included that compared two types of MAT
for pregnant women with OUD.

•
Image from archives.drugabuse.gov

Exclusions: articles that focused on
maternal outcomes, focused on cost, or
unoriginal research.

Each quantitative article reviewed was able
to produce data that showed rates of OUD
and NAS are rising significantly.

•

MAT for pregnant women with OUD is
associated with better health outcomes for
infants, including a shorter hospital stay and
less severe NAS symptoms (Okoroh et al.,
2017).

•

When comparing methadone and
buprenorphine as MAT for women with
OUD, neither had increasingly more risks or
decreased health outcomes for the infant
than the other (Zedler et al., 2016).

NAS rates per 1000
birth hospitalizations

•

Most pregnancies among women with OUD
are unintended (Hurley et al., 2020).
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Implications
•

Further research would benefit from
examining the degree to which the infant
was exposed to opioids, how long the
mother had been using MAT, and whether
the mother used opioids while taking MAT.

•

Further research would also benefit from
separating cases of NAS associated with
illicit drugs versus opioids.

•

Rates of NAS among infants born to women
with OUD would decrease if they had safe,
easy, low-cost access to contraceptives
(Hurley et al., 2020).

•

Healthcare professionals need to focus on
providing unbiased care that addresses all
the patient’s needs and educate the patient
on comprehensive treatment plans to
reduce and prevent NAS.

•

Patient-centered care could help decrease
negative health outcomes for both women
with OUD and their infants.

(Hirai et al., 2021)
•

85.7% of women studied with OUD were
not actively trying to get pregnant, but over
half did not utilize any pregnancy prevention
method (Hurley et al., 2020).

•

The most important barriers for women with
OUD trying to obtain contraception were
awareness and access to services (Hurley
et al., 2020).

•

The rate of NAS increased from 2.1 to 8.0 in
1000 live-births from 2003 to 2013 (Okoroh
et al., 2017).

Literature Review & Methods
•

•

The states with more than 20 cases of NAS
per 1000 births in 2017 were:
State

Mortality was 1.0% among infants with NAS
compared with 0.29% among infants
without NAS (Witt et al., 2017).
NAS related hospital admissions increased
by more than fourfold between 2003 and
2012. The increase raised the annual cost
for the U.S. from $61 million to $316 million,
respectively. (Corr & Hollenbeak, 2017).

NAS was more common among the white,
Medicaid-dependent population and lowincome households (Corr & Hollenbeak,
2017).

•

18.8%

(Okoroh et al., 2017)
•

Conclusions

Findings

•

The ability to analyze the relationship
between MAT and fetal death was limited
due to inconsistent reporting of point in
gestation and treatment (Zedler et al.,
2016).

•

There was no measurable difference in the
congenital anomaly risk among women that
received MAT (Zedler et al., 2016).

•

Preterm birth risk was lower in women
treated with buprenorphine than with
methadone (Zedler et al., 2016).
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